Institute for Wealth Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Institute for Wealth Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.07K	Buy	+2	New	+$1.02K	﹤0.01%	1650

Other funds holding MDGL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

EAM

EULAV Asset Management Sarasota, Florida $3.13B AUM 23.04% 1-Year Est. Return

Institute for Wealth Management's MDGL Position: Q2 2026 in Review

Institute for Wealth Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 2 shares worth $1.07K. The stake represents ﹤0.01% of the portfolio and ranks #1650 among its holdings.

163 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Institute for Wealth Management held 2 shares of Madrigal Pharmaceuticals worth $1.07K as of Q2 2026.
Madrigal Pharmaceuticals was a new Institute for Wealth Management position in Q2 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of Institute for Wealth Management's portfolio in Q2 2026, its #1650 holding.
163 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Institute for Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.